09.05.2012 - Austrian biotech company Intercell AG has signed a €25m financing deal with Swiss investor BB BiotechAG.
Vienna – The vaccine maker also said it is in talks with other investors concerning a private stock placement that could total €15m. The investment, through a fully owned subsidiary of BB Biotech AG, consists of a €20m secured loan and a commitment to invest €5m as part of a proposed private share placement. Intercell’s CEO, Thomas Lingelbach, stated: “Following the successful strategic resetting in 2011, this financing marks an important step in the renewal of Intercell as a notable biotech vaccine company. With growing sales from our first product on the market, a diversified pipeline and technology base and a disciplined financial strategy, we are now very well positioned for the next development phase of our company.”
Intercell is trying to get back on track after several product setbacks sparked worries about its pipeline prospects. After a setback in the development of a traveller’s diarrhoea vaccine last year, the new focus of the company is on vaccines preventing nosocomial infections. The secured six-year loan carries a variable interest rate. Intercell will pay BB Biotech royalties on sales revenues from its product Ixiaro, a vaccine for Japanese encephalitis. The €5m equity investment will see BB Biotech subscribe for nearly 2 million Intercell shares for about 2.55 € per share as part of the private placement. According to Intercell, existing shareholders will not get subscription rights for the placement
28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.
20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck.
13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.
09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.